SCHEMBL400774

SCHEMBL400774

COc1cccc(OC)c1Cc1nc2cc(C(=O)O)ccc2c(=O)[nH]1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE5A O76074 1/20 0.62
KDM4E B2RXH2 5/20 0.60
RECQL P46063 1/20 0.60
POLB P06746 2/20 0.49
ALDH1A1 P00352 5/20 0.48
MAPK1 P28482 3/20 0.48
TDP1 Q9NUW8 2/20 0.47
ALOX15 P16050 2/20 0.46
USP2 O75604 1/20 0.46
TNKS O95271 3/20 0.45
TNKS2 Q9H2K2 1/20 0.45
PARP2 Q9UGN5 1/20 0.45
SMN1; SMN2 Q16637 2/20 0.44
HTT P42858 1/20 0.44
RAB9A P51151 1/20 0.44
HSD17B10 Q99714 2/20 0.43
MAPT P10636 2/20 0.43
NPSR1 Q6W5P4 1/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL405782 0.88 POLB (0.59) PDE5AKDM4ERECQLPOLBALDH1A1
SCHEMBL404827 0.87 PDE5A (0.58) PDE5AKDM4ERECQLPOLBALDH1A1
SCHEMBL404979 0.85 PDE5A (0.69) PDE5AKDM4ERECQLPOLBALDH1A1
SCHEMBL403796 0.83 PDE5A (0.64) PDE5AKDM4ERECQLPOLBALDH1A1
SCHEMBL400622 0.83 PDE5A (0.65) PDE5AKDM4ERECQLPOLBTNKS2
SCHEMBL404603 0.83 PDE5A (0.72) PDE5AKDM4ERECQLPOLBALDH1A1
SCHEMBL405904 0.83 KDM4E (0.58) PDE5AKDM4ERECQLPOLBALDH1A1
SCHEMBL401317 0.83 PDE5A (0.62) PDE5AKDM4ERECQLPOLBALDH1A1
SCHEMBL404328 0.83 PDE5A (0.60) PDE5AKDM4ERECQLPOLBALDH1A1
SCHEMBL401645 0.83 PDE5A (0.72) PDE5AKDM4ERECQLPOLBALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2050739-B1 QUINAZOLINE DERIVATIVE ASKA PHARM CO LTD (JP) 2016-07-06 EP disclosed
CN-101501007-B Quinazoline derivative ASKA PARMACEUTICAL CO LTD 2014-01-29 CN disclosed
US-8101624-B2 Quinazoline derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2012-01-24 US disclosed
US-20100113484-A1 TREATING AGENT OF UROPATHY ASKA PHARMACEUTICAL CO., LTD. (JP) 2010-05-06 US disclosed
US-20090318478-A1 QUINAZOLINE DERIVATIVES ASKA PHARMACEUTICAL CO., LTD. 2009-12-24 US disclosed
EP-2123301-A1 THERAPEUTIC AGENT FOR URINARY TRACT DISEASE ASKA Pharmaceutical Co., Ltd. (JP) 2009-11-25 EP disclosed
EP-2050739-A1 QUINAZOLINE DERIVATIVE ASKA Pharmaceutical Co., Ltd. (JP) 2009-04-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113484-A1 TREATING AGENT OF UROPATHY BPHL, PDE12, UROD PDE5A 14/4885KDM4E 4291/4885RECQL 878/4885
US-20090318478-A1 QUINAZOLINE DERIVATIVES PDE9A, PDE3A, PDE5A PDE5A 3/4885KDM4E 2869/4885RECQL 100/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.